EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Apremilast for the treatment of psoriasis and psoriatic arthritis

Steve Chaplin

Future Prescriber · 2013

DOI: 10.1002/fps.102 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract Apremilast, an orally active inhibitor of phosphodiesterase 4 that inhibits several inflammatory cytokines, is being developed for the treatment of psoriasis and psoriatic arthritis. This Drug profile reviews the clinical data to date. Copyright © 2013 John Wiley & Sons, Ltd.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →